Conference Day One
Thursday November 21
8:00 am Check-In & Light Breakfast
8:50 am Chair’s Opening Remarks
Advancing MRD Detection through Technological Innovation & Expanding Patient Access to Liquid Biopsies for Transformative Patient Surveillance
9:00 am Revolutionizing Cancer Care with MRD & Multi-Omics Liquid Biopsies Enhanced by Cutting-Edge Technologies for Unparalleled Patient Monitoring
Synopsis
• How novel technologies combined with multi-omic approaches significantly enhance the detection and quantification of circulating tumor markers
• Advancements improving the accuracy of identifying genetic variations in malignancies
• Leveraging AI and ML to analyze complex multi-omic data, leading to more accurate prognoses and personalized treatments
9:30 am Session Details to be Confirmed
Synopsis
Session Hosted by Foundation Medicine.
Details to be announced soon.
10:00 am Equity, Diversity & Inclusion Fireside Chat: Exploiting Liquid Biopsies to Boost Inclusivity in Clinical Trials to Elevate Patient Surveillance & Elevate Survival Rates in Oncology
Synopsis
• How could liquid biopsies provide better precision healthcare surveillance options for patients in economically deprived areas?
• How to utilize liquid biopsies to increase diverse populations in clinical trials to ensure comprehensive and equitable outcomes
• Analysing the impact of low-cost tests in enhancing the inclusion of diverse populations in clinical studies to improve accessibility to precision therapeutics
10:30 am Incorporating MRD Detection & Cell-Free DNA into Clinical Trials: A Comprehensive Overview
Synopsis
• Advanced patient selection strategies in clinical trials: Leveraging cell-free DNA (cfDNA) for precise patient stratification and selection to enhance trial outcomes and personalized medicine
• Innovative detection of minimal residual disease (MRD) and patient surveillance: Utilizing cfDNA as a cutting-edge tool for monitoring MRD and conducting ongoing patient surveillance, improving early detection and intervention
• Technological innovation: Understanding the impact of novel technologies on MRD detection and ctDNA analysis
11:00 am Morning Break & Speed Networking
Synopsis
As the clinical biomarkers and Liquid Biopsy community unite once more, this valuable session will ensure that you can connect with your peers in the room to make new and lasting connections. All attendees will have the opportunity to meet and network with their industry peers.
Leveraging Liquid Biopsies to Optimize Patient Selection in Clinical Trials to Develop Safer & More Efficacious Drugs for Patients in Need
12:00 pm Challenges & Strategies of LBx Assays Clinical Validation for Cancer Surveillance
Synopsis
- Incorporating liquid biopsy (LBx) based surveillance in clinical settings: Implementation of LBx surveillance assays is beneficial for patient management
- Managing hurdles of clinical validation: As more LBx assays intended for surveillance are emerging, we must address various challenges associated with assay clinical validation
- Strategies to facilitate clinical validation: Let’s explore strategies to overcome these challenges and ensure robust clinical validation of LBx assays
12:30 pm Session Details to be Confirmed
Synopsis
Session hosted by Burning Rock Dx.
Details to be revealed soon.
1:00 pm Association of Baseline ctDNA Genetics with Outcomes in Taxane-Naïve Patients with mCRPC Treated with [177Lu]Lu-PSMA-617 Versus Change of ARPI in PSMAfore
Synopsis
• Higher baseline ctDNA fraction was associated with shorter rPFS across both treatment arms
• Genetic alterations detected at >10% frequency in ctDNA were consistent with key driver alterations detected in tumor tissues from mCRPC patients reported in literature
• 8q amplifications, AR amplification, and TP53 deleterious alterations are prognostic biomarkers that were associated with shorter rPFS and decreased tumor response in the 177Lu-PSMA-617 arm
1:30 pm Lunch & Networking Break
Optimizing ctDNA Analysis for Tailored Dosage Regimens to Advance Precision in Clinical Decision-Making
2:30 pm Leveraging Liquid Biopsies for Precision Dosage Guidance & Oncology Surveillance
Synopsis
• Project Optimus: Explore how liquid biopsy data can be utilized to refine dosage strategies in clinical trials
• Exploring the limitations and emerging solutions in applying liquid biopsies across various tumor types
• Utilizing liquid biopsies as a surrogate endpoint to support RECIST readouts
3:00 pm Finding Value in ctDNA Monitoring for Decision Making in Early-Phase Drug Development
Synopsis
• Utility of ctDNA in drug discovery and optimizing decision-making
• Monitoring to better refine efficacy signals
• Monitoring for resistance to PARP inhibitors; assay details matter
3:30 pm Panel Discussion: Supercharging Oncology Therapeutics with Unprecedented Patient Surveillance to Minimize Risk of Relapse & Improve Survival
Synopsis
• Leveraging MRD to act as a biomarker for patient relapse
• Developing surrogate endpoints using ctNDA
• Investigating the potential of multi-markers in advancing patient monitoring
4:00 pm Afternoon Networking Break
Harnessing MRD to Enhance Relapse Prediction & Strengthen Surveillance Strategies for Unprecedented Patient Care
4:40 pm Pioneering the Future of Cancer Care: Predicting Relapse with Biomarkers
Synopsis
• It is feasible of developing biomarkers from liquid biopsies in ALL and AML as evidenced from 2 projects in hematologic conditions
• MRD can be used as a prognostic indicator. Efforts are underway to develop biomarkers for progression from MGUS to Multiple Myeloma
• Inclusion of patient advocacy groups and patients with lived experience provides valuable insight into patient needs and needed data to improve patient outcomes
5:10 pm BioNTech – a Global Immunotherapy Powerhouse ctDNA Testing to Identify Patients with CRC at Risk of Recurrence after Curative Intent Surgery
Synopsis
• How to leverage new technologies to improve identification of patients and refine selection?
• Improving early cancer diagnostic testing accuracy
• Leveraging liquid biopsies to developing prognostic biomarkers